Greg Williams

Clayton Utz
Partner Sydney

All matters involving pharma companies seem to cross his path; everybody goes to Greg, he's so well regarded and respected.

– Chambers Asia Pacific


Greg is internationally recognised by clients and legal directories as a leading litigator in class actions, product liability litigation and regulatory matters across the pharmaceutical, medical devices and automotive industries.

Greg is the National Practice Group Leader of the Commercial Litigation team.

Notable Work
  • Bayer: acting in a class action commenced in the Victorian Supreme Court relating to the Essure contraceptive device. The first instance trial completed in August 2023 and judgment is currently reserved.
  • VW Group: acted in five consumer class actions in the Federal Court of Australia, in respect of diesel emissions. Those class actions were case managed together with ACCC enforcement proceedings. All matters were settled in late 2019 and the class action settlements were approved by the Court in 2020.
  • Subaru Australia: acted in the defence of the Takata Airbag class actions.
  • App platform: acting in class action proceedings commenced on behalf of consumers and developers seeking compensation arising from alleged overpayments on in-app purchases.
  • Hino Motors: acting in a class action in relation to alleged misconduct concerning engine certification of certain Hino diesel vehicles.
  • Commonwealth Bank: acted in the Storm Financial Class Action. This matter ran to trial in 2013, but was settled in late 2014 before judgment was delivered.
  • Merck & Co., Inc. and Merck Sharp & Dohme (Australia) Pty Limited: acted successfully for in the Vioxx class action, including appearing as junior counsel at the first instance trial.
  • Novartis AG: acted for in in litigation against the Department of Health in respect of the Minister's refusal to exercise discretion to reverse a price reduction.
  • Various clients: acts for clients in relation to the operation of the Pharmaceutical Benefits Scheme, including strategy for engaging with the Department of Health on major and minor submissions to the PBAC and rights of review and appeal from recommendations of the PBAC.
  • GD Searle & Co and Monstanto Corporation: acted successfully in the Australian proceedings involving the Gravigard (Copper 7) intrauterine contraceptive device.
Find other people to support you